Business
Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Results from the trial, which will begin dosing on April 6, aren’t likely until September.
Under terms of the agreement, Charles River Laboratories will be able to provide its clients with the use of Deciphex’s flagship product.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
In addition to the impact on conferences and large meetings, many companies have implemented restrictions on face-to-face meetings between sales reps and clients.
The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.
Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need
Doudna announced she is converting a 2,500-square-foot scientific lab at Berkeley’s Innovative Genomics Institute into a lab for testing for the novel coronavirus that causes COVID-19.
First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases